Connor, Clark & Lunn Investment Management (CC&L)’s Larimar Therapeutics LRMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$311K Buy
69,087
+48,017
+228% +$192K ﹤0.01% 1414
2025
Q4
$80.3K Buy
+21,070
New +$81.9K ﹤0.01% 1490
2024
Q4
Sell
-23,521
Closed -$154K 1531
2024
Q3
$154K Sell
23,521
-311
-1% -$2.5K ﹤0.01% 1347
2024
Q2
$173K Sell
23,832
-34,284
-59% -$263K ﹤0.01% 1275
2024
Q1
$441K Buy
+58,116
New +$453K ﹤0.01% 1149
2023
Q4
Sell
-21,835
Closed -$86.2K 1486
2023
Q3
$86.2K Sell
21,835
-26,239
-55% -$99.2K ﹤0.01% 1303
2023
Q2
$150K Buy
48,074
+6,227
+15% +$25.4K ﹤0.01% 1222
2023
Q1
$190K Buy
41,847
+4,362
+12% +$22.8K ﹤0.01% 1105
2022
Q4
$155K Buy
37,485
+24,420
+187% +$83.3K ﹤0.01% 1082
2022
Q3
$42K Buy
+13,065
New +$32.7K ﹤0.01% 1069
2019
Q3
Sell
-9,889
Closed -$141K 1031
2019
Q2
$141K Sell
9,889
-10,952
-53% -$292K ﹤0.01% 934
2019
Q1
$685K Buy
20,841
+296
+1% +$15.2K ﹤0.01% 608
2018
Q4
$1.22M Buy
20,545
+1,385
+7% +$137K 0.01% 511
2018
Q3
$2.69M Buy
19,160
+3,158
+20% +$383K 0.02% 397
2018
Q2
$1.96M Buy
16,002
+1,233
+8% +$105K 0.01% 480
2018
Q1
$1.32M Buy
14,769
+959
+7% +$81.3K 0.01% 448
2017
Q4
$766K Hold
13,810
﹤0.01% 558
2017
Q3
$583K Hold
13,810
﹤0.01% 614
2017
Q2
$582K Buy
13,810
+2,091
+18% +$107K ﹤0.01% 577
2017
Q1
$655K Buy
11,719
+2,244
+24% +$111K ﹤0.01% 578
2016
Q4
$362K Buy
9,475
+1,031
+12% +$41.8K ﹤0.01% 677
2016
Q3
$335K Buy
8,444
+1,992
+31% +$90.5K ﹤0.01% 651
2016
Q2
$464K Buy
6,452
+1,442
+29% +$114K ﹤0.01% 594
2016
Q1
$402K Buy
5,010
+608
+14% +$48K ﹤0.01% 601
2015
Q4
$332K Buy
4,402
+3,510
+393% +$564K ﹤0.01% 610
2015
Q3
$342K Buy
+892
New +$402K ﹤0.01% 579

Other funds holding LRMR